Suprefort
Fat LossKhavinson bioregulator / researchExperimental
Short peptide marketed as a hepatic bioregulator. Not FDA-approved.
For research use only.
Key Facts
- CAS
- 167174-49-0
- Molecular Weight (MW)
- 391.39 g/mol
- Half-life
- Not established (small tripeptide)
- Unit
- mcg
- Administration Route
- —
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- Hepatocytes (proposed)
Overview
Short peptide marketed as a hepatic bioregulator. Not FDA-approved.
Protocol
- Dosage Range
- Per research protocol
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Science
Mechanism of Action
Claimed to normalize hepatocyte protein synthesis in older bioregulator papers. No modern registration trials.
Targets
Hepatocytes (proposed)
Studies
- Khavinson bioregulators— Journal/year not available
Benefits
Historical liver-bioregulator category
Potential Side Effects
- Not characterized
References
- PMID 15587334External link · Year —